Response to the comments from Drs Shimazawa and Ikeda

Comment

Rashmi R Shah et al. Br J Clin Pharmacol. 2013 May.

. 2013 May;75(5):1368-9.

doi: 10.1111/j.1365-2125.2012.04461.x.

No abstract available

Comment on

Personalized medicine: is it a pharmacogenetic mirage?
Shah RR, Shah DR. Shah RR, et al. Br J Clin Pharmacol. 2012 Oct;74(4):698-721. doi: 10.1111/j.1365-2125.2012.04328.x. Br J Clin Pharmacol. 2012. PMID: 22591598 Free PMC article. Review.
Are there any differences in the regulations of personalized medicine among the USA, EU and Japan?
Shimazawa R, Ikeda M. Shimazawa R, et al. Br J Clin Pharmacol. 2013 May;75(5):1365-7. doi: 10.1111/j.1365-2125.2012.04462.x. Br J Clin Pharmacol. 2013. PMID: 22978372 Free PMC article. No abstract available.

1. Shimazawa R, Ikeda M. Are there any differences in the regulations of personalized medicine among the USA, EU, and Japan? Br J Clin Pharmacol. 2013;75:1365–1367. - PMC - PubMed
1. Shah RR. Pharmacogenetics, ethnic differences in drug response and drug regulation. In: Saurez-Kurtz G, editor. Pharmacogenomics in Admixed Populations. Austin, TX: Landes Bioscience; 2007. pp. 180–197.
1. Kosugi Y, Hirabayashi H, Igari T, Fujioka Y, Hara Y, Okuda T, Moriwaki T. Evaluation of cytochrome P450-mediated drug-drug interactions based on the strategies recommended by regulatory authorities. Xenobiotica. 2012;42:127–138. - PubMed
1. European Medicines Agency. Applications in the centralised procedure: an analysis of outcomes (CPMP/602/00). European Medicines Agency, London, 15 March 2000. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Other/2009/10/WC500... [last accessed 2 September 2012]
1. Food and Drug Administration. New Drug Review 2009 Updates. Presentation by Jenkins JK. FDA/CMS Summit, 3 December 2009. Available at: http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/UCM192786.pdf [last accessed 2 September 2012]